

Supplemental Tables for:
 Female representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies
 Jonathan M Loree et al.

Supplementary Table 1: Ratio of females to males (female:male) in trials reviewed by tumor type, for incidence and for mortality in the US population.

Cancer Type	Female:male in trials and for incidence and mortality in the US population			Odds Ratio (OR) for female trial enrollment compared to incidence and mortality in the US population	
	Trial enrollment	Incidence	Mortality	Incidence (95% CI, P value)	Mortality (95% CI, P value)
All Cancers*	0.67	0.70	0.74	0.97 (0.95-0.98, <0.0001)	0.91 (0.90-0.93, <0.0001)
Leukemia	0.68	0.71	0.69	0.95 (0.91-0.998, 0.040)	0.99 (0.94-1.56, 0.73)
Lymphoma	0.78	0.82	0.75	0.95 (0.90-0.997, 0.040)	1.04 (0.98-1.10, 0.18)
Multiple Myeloma	0.76	0.77	0.81	0.99 (0.93-1.05, 0.63)	0.94 (0.44-1.00, 0.067)
Lung**	0.67	0.87	0.87	0.77 (0.75-0.80, <0.0001)	0.77 (0.75-0.80, <0.0001)
Colorectal	0.66	0.92	0.91	0.72 (0.69-0.76, <0.0001)	0.73 (0.69-0.78, <0.0001)
Pancreas ***	0.77	0.91	0.93	0.85 (0.78-0.93, 0.0004)	0.84 (0.76-0.91, <0.0001)
Kidney	0.38	0.59	0.49	0.63 (0.60-0.67, <0.0001)	0.76 (0.71-0.82, <0.0001)
Bladder	0.41	0.30	0.38	1.34 (1.21-1.48, <0.0001)	1.06 (0.95-1.17, 0.29)
Melanoma	0.72	0.70	0.53	1.04 (1.00-1.09, 0.066)	1.37 (1.29-1.45, <0.0001)
Thyroid	0.82	3.20	1.11	0.26 (0.23-0.28, <0.0001)	0.74 (0.65-0.85, <0.0001)

Caption: Odds Ratio (OR) for female trial enrollment compared to US population female incidence or mortality by tumor type. Population data is per the International Agency for Research on Cancer (IARC). CI: Confidence Interval. *Sex-specific cancers excluded. **There were no small cell lung cancer (SCLC) trials in this trial cohort. IARC data includes SCLC and non-SCLC. ***Includes adenocarcinoma and neuroendocrine tumors of the pancreas.

Supplementary Table 2: Ratio of females to males (female:male) in trials reviewed by tumor type, for incidence and mortality in very high human development index (HDI) countries.

Cancer Type	Female:male enrollment in trials and for incidence and mortality in very high HDI countries			Odds Ratio (OR) for female trial enrollment compared to incidence and mortality in very high HDI countries	
	Trial enrollment	Incidence	Mortality	Incidence (95% CI, P value)	Mortality (95% CI, P value)
All Cancers*	0.67	0.68	0.66	0.99 (0.98-1.01, 0.32)	1.02 (1.01-1.04, 0.0023)
Leukemia	0.68	0.74	0.76	0.92 (0.88-0.96, <0.0001)	0.90 (0.86-0.94, <0.0001)
Lymphoma	0.78	0.82	0.79	0.95 (0.91-0.997, 0.039)	0.98 (0.94-1.03, 0.53)
Multiple Myeloma	0.78	0.81	0.88	0.94 (0.89-0.997, 0.040)	0.86 (0.41-0.91, <0.0001)
Lung**	0.67	0.62	0.56	1.08 (1.05-1.12, <0.0001)	1.21 (1.17-1.25, <0.0001)
Colorectal	0.66	0.83	0.88	0.80 (0.76-0.84, <0.0001)	0.76 (0.72-0.80, <0.0001)
Pancreas ***	0.77	0.97	0.97	0.80 (0.73-0.88, <0.0001)	0.80 (0.73-0.87, <0.0001)
Kidney	0.38	0.57	0.55	0.66 (0.62-0.70, <0.0001)	0.69 (0.65-0.73, <0.0001)
Bladder	0.41	0.29	0.36	1.41 (1.28-1.56, <0.0001)	1.14 (1.03-1.26, 0.0098)
Melanoma	0.72	0.88	0.69	0.83 (0.79-0.86, <0.0001)	1.05 (0.50-1.10, 0.021)
Thyroid	0.82	3.37	1.51	0.24 (0.22-0.27, <0.0001)	0.55 (0.49-0.61, <0.0001)

Caption: Odds Ratio (OR) for female trial enrollment compared to very high HDI country female incidence or mortality by tumor type. Population data is as per the International Agency for Research on Cancer (IARC). CI: Confidence Interval. *Sex-specific cancers excluded. **There were no small cell lung cancer (SCLC) trials in this trial cohort. IARC data includes SCLC and non-SCLC. ***Includes adenocarcinoma and neuroendocrine tumors of the pancreas.

Supplementary Table 3: Ratio of females to males (female:male) for incidence and mortality compared to a global population.

Cancer Type	Female:male enrollment in trials and for incidence and mortality globally			Odds Ratio (OR) for female trial enrollment compared to incidence and mortality globally	
	Trial enrollment	Incidence	Mortality	Incidence (95% CI, P value)	Mortality (95% CI, P value)
All Cancers*	0.67	0.65	0.59	1.04 (1.02-1.06, <0.0001)	1.15 (1.13-1.17, <0.0001)
Leukemia	0.68	0.75	0.72	0.90 (0.86-0.94, <0.0001)	0.94 (0.90-0.98, 0.0070)
Lymphoma	0.78	0.78	0.70	1.00 (0.95-1.04, 0.88)	1.11 (1.06-1.16, <0.0001)
Multiple Myeloma	0.78	0.78	0.80	0.98 (0.92-1.03, 0.37)	0.95 (0.90-1.00, 0.049)
Lung**	0.67	0.53	0.49	1.27 (1.23-1.31, <0.0001)	1.39 (1.35-1.43, <0.0001)
Colorectal	0.66	0.80	0.82	0.83 (0.79-0.87, <0.0001)	0.81 (0.77-0.85, <0.0001)
Pancreas ***	0.77	0.89	0.90	0.87 (0.80-0.95, 0.0025)	0.86 (0.78-0.94, 0.0006)
Kidney	0.38	0.58	0.54	0.64 (0.61-0.68, 0.0001)	0.70 (0.66-0.74, <0.0001)
Bladder	0.41	0.30	0.35	1.38 (1.25-1.52, <0.0001)	1.17 (1.06-1.29, 0.0022)
Melanoma	0.72	0.91	0.74	0.80 (0.77-0.83, <0.0001)	0.98 (0.93-1.02, 0.26)
Thyroid	0.82	3.33	1.64	0.25 (0.22-0.27, <0.0001)	0.50 (0.45-0.56, <0.0001)

Caption: Odds Ratio (OR) for female trial enrollment compared to global incidence and mortality by tumor type. Population data is as per the International Agency for Research on Cancer (IARC). CI: Confidence Interval. *Sex-specific cancers excluded. **There were no small cell lung cancer (SCLC) trials in this trial cohort. IARC data includes SCLC and non-SCLC. ***Includes adenocarcinoma and neuroendocrine tumors of the pancreas.

